SBIO.L vs. XLVS.L
SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and XLVS.L (Invesco Health Care S&P US Select Sector UCITS ETF Acc) are both Health & Biotech Equities funds from Invesco - SBIO.L tracks the NASDAQ Biotechnology TR USD while XLVS.L tracks the S&P® Select Sector Capped 20% Health Care Index. Both are passively managed. Over the past 10 years, SBIO.L returned 7.61%/yr vs 9.39%/yr for XLVS.L. A 0.72 correlation means they provide meaningful diversification when combined. SBIO.L charges 0.40%/yr vs 0.14%/yr for XLVS.L.
Performance
SBIO.L vs. XLVS.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO.L achieves a 3.96% return, which is significantly higher than XLVS.L's -0.36% return. Over the past 10 years, SBIO.L has underperformed XLVS.L with an annualized return of 7.61%, while XLVS.L has yielded a comparatively higher 9.39% annualized return.
SBIO.L
- 1D
- -0.36%
- 1M
- -0.99%
- YTD
- 3.96%
- 6M
- 3.33%
- 1Y
- 40.92%
- 3Y*
- 12.87%
- 5Y*
- 4.59%
- 10Y*
- 7.61%
XLVS.L
- 1D
- 1.77%
- 1M
- 6.08%
- YTD
- -0.36%
- 6M
- 1.25%
- 1Y
- 17.28%
- 3Y*
- 7.45%
- 5Y*
- 6.13%
- 10Y*
- 9.39%
SBIO.L vs. XLVS.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 3.96% | 32.89% | -2.00% | 6.15% | -11.85% | -0.49% | 27.35% | 25.54% | -11.34% | 21.45% |
XLVS.L Invesco Health Care S&P US Select Sector UCITS ETF Acc | -0.36% | 14.78% | 2.15% | 1.56% | -2.62% | 27.57% | 12.04% | 20.54% | 4.87% | 21.27% |
Correlation
The correlation between SBIO.L and XLVS.L is 0.67, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.67 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.62 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.65 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.69 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2014 | 0.72 |
The correlation between SBIO.L and XLVS.L has been stable across timeframes, ranging from 0.62 to 0.72 - a consistent structural relationship.
SBIO.L vs. XLVS.L - Sectors Allocation Comparison
Sectors
SBIO.L
XLVS.L
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
SBIO.L
XLVS.L
Basic Materials
SBIO.L
-
XLVS.L
-
Communication Services
SBIO.L
-
XLVS.L
-
Consumer Cyclical
SBIO.L
-
XLVS.L
-
Consumer Defensive
SBIO.L
-
XLVS.L
-
Energy
SBIO.L
-
XLVS.L
-
Financial Services
SBIO.L
-
XLVS.L
-
Industrials
SBIO.L
-
XLVS.L
-
Real Estate
SBIO.L
-
XLVS.L
-
Technology
SBIO.L
-
XLVS.L
-
Utilities
SBIO.L
-
XLVS.L
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO.L vs. XLVS.L — Risk / Return Rank
SBIO.L
XLVS.L
SBIO.L vs. XLVS.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and Invesco Health Care S&P US Select Sector UCITS ETF Acc (XLVS.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO.L | XLVS.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.93 | ||
| Sortino ratioReturn per unit of downside risk | +1.18 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.20 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 5.33 | 1.65 | +3.68 |
| Martin ratioReturn relative to average drawdown | 16.33 | 4.06 | +12.27 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO.L | XLVS.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.07 | 1.14 | +0.93 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.42 | -0.20 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | 0.60 | -0.26 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 0.74 | -0.47 |
Drawdowns
SBIO.L vs. XLVS.L - Drawdown Comparison
The maximum SBIO.L drawdown since its inception was -39.44%, which is greater than XLVS.L's maximum drawdown of -26.88%. Use the drawdown chart below to compare losses from any high point for SBIO.L and XLVS.L.
Loading charts...
Drawdown Indicators
| SBIO.L | XLVS.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.44% | -26.88% | -12.56% |
Max Drawdown (1Y)Largest decline over 1 year | -7.65% | -10.45% | +2.80% |
Max Drawdown (3Y)Largest decline over 3 years | -26.89% | -17.56% | -9.33% |
Max Drawdown (5Y)Largest decline over 5 years | -38.33% | -17.56% | -20.77% |
Max Drawdown (10Y)Largest decline over 10 years | -38.33% | -26.88% | -11.45% |
Current DrawdownCurrent decline from peak | -3.18% | -2.93% | -0.25% |
Average DrawdownAverage peak-to-trough decline | -16.83% | -4.53% | -12.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.50% | 4.24% | -1.74% |
Volatility
SBIO.L vs. XLVS.L - Volatility Comparison
Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 6.36% compared to Invesco Health Care S&P US Select Sector UCITS ETF Acc (XLVS.L) at 5.12%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than XLVS.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO.L | XLVS.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.36% | 5.12% | +1.24% |
Volatility (6M)Calculated over the trailing 6-month period | 15.25% | 10.88% | +4.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.67% | 15.15% | +4.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.22% | 14.76% | +6.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.24% | 15.54% | +6.70% |
SBIO.L vs. XLVS.L - Expense Ratio Comparison
SBIO.L has a 0.40% expense ratio, which is higher than XLVS.L's 0.14% expense ratio.
Dividends
SBIO.L vs. XLVS.L - Dividend Comparison
Neither SBIO.L nor XLVS.L has paid dividends to shareholders.
Frequently Asked Questions
SBIO.L and XLVS.L have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, XLVS.L is cheaper at 0.14% per year. The better choice depends on whether you care most about return, fees, risk, or income.
XLVS.L is cheaper with a 0.14% expense ratio, compared with 0.40% for SBIO.L.
SBIO.L tracks NASDAQ Biotechnology TR USD, while XLVS.L tracks S&P® Select Sector Capped 20% Health Care Index. Their fees differ too: 0.40% for SBIO.L and 0.14% for XLVS.L.
Find the right allocation for SBIO.L and XLVS.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer